Category: Pharmaceuticals
Global Pharmaceuticals
-
Sports Nutrition Supplements
... by 2030, growing at a CAGR of 5.8% over the analysis period 2023-2030. Amino Acids / Derivatives, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$4.6 ... Read More
-
Dental Preventive Supplies
... by 2030, growing at a CAGR of 4.2% over the analysis period 2023-2030. The U.S. Market is Estimated at US$151.4 Million While China is Forecast to Grow at 6.4% CAGR The Dental Preventive Supplies market ... Read More
-
Global Biosimilar Monoclonal Antibody Market Research Report 2024(Status and Outlook)
... produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies. Biosimilar Monoclonal Antibodies refer to the biologic ... Read More
-
Synthetic Biology
... at a CAGR of 28.0% over the analysis period 2023-2030. Oligonucleotides & Synthetic DNA, one of the segments analyzed in the report, is expected to record a 29.3% CAGR and reach US$39.5 Billion by the ... Read More
-
Wearable Fitness Technology
... by 2030, growing at a CAGR of 13.4% over the analysis period 2023-2030. Smartwatches, one of the segments analyzed in the report, is expected to record a 15.0% CAGR and reach US$11.0 Billion by the ... Read More
-
Narcolepsy Therapeutics
... at a CAGR of 7.2% over the analysis period 2023-2030. Narcolepsy with Cataplexy Therapeutics, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$1.9 Billion by the ... Read More
-
High Temperature Insulation (HTI)
... reach US$9.2 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2023-2030. Ceramic Fibers, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach ... Read More
-
Orthopedic Devices
... at a CAGR of 6.3% over the analysis period 2023-2030. Joint Reconstruction Devices, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$44.6 Billion by the end ... Read More
-
EEG, EMG and Evoked Potential Devices
... the year 2023, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2023-2030. Electroencephalograph Equipment, one of the segments analyzed in the report, is expected to ... Read More
-
Antibacterial Drugs
... at a CAGR of 3.9% over the analysis period 2023-2030. ß-lactams Drug Class, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$35.4 Billion by the end ... Read More
-
Biosimilars
... of 20.1% over the analysis period 2023-2030. Recombinant Non-glycosylated Proteins, one of the segments analyzed in the report, is expected to record a 20.5% CAGR and reach US$62.4 Billion by the end of the analysis ... Read More
-
Food Allergy and Intolerance Products
... is expected to reach US$53.9 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030. Lactose-Free Products, one of the segments analyzed in the report, is expected to record a 5.1% ... Read More
-
Overactive Bladder (OAB) Therapeutics
... reach US$1.5 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2023-2030. Anticholinergics Therapy, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach ... Read More
-
Bone and Joint Health Supplements
... is expected to reach US$22.0 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2023-2030. Joint Supplements, one of the segments analyzed in the report, is expected to record a 6.3% ... Read More
-
Testosterone Replacement Therapy (TRT)
... reach US$2.5 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2023-2030. TRT Topicals, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach ... Read More
-
Irritable Bowel Syndrome (IBS) Therapeutics
... is expected to reach US$3.4 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2023-2030. IBS-D Therapeutics, one of the segments analyzed in the report, is expected to record a 6.9% ... Read More
-
Peptic Ulcer Testing
... by 2030, growing at a CAGR of 5.5% over the analysis period 2023-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$410.6 Million by ... Read More
-
Infection Surveillance Solutions
... by 2030, growing at a CAGR of 14.2% over the period 2023-2030. Infection Surveillance Software, one of the segments analyzed in the report, is expected to record 13.7% CAGR and reach US$1.2 Billion by the ... Read More
-
Enteral Feeding Pumps
... by 2030, growing at a CAGR of 6.1% over the analysis period 2023-2030. Neurological Disorders Application, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$751.7 Million ... Read More
-
Online Music Streaming
... by 2030, growing at a CAGR of 15.9% over the analysis period 2023-2030. Audio Streaming, one of the segments analyzed in the report, is expected to record a 14.4% CAGR and reach US$42.7 Billion by ... Read More
-
Nano-Magnetic Devices
... at a CAGR of 5.5% over the analysis period 2023-2030. Nano-Magnetic Sensors, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$12.8 Billion by the end of ... Read More
-
Breast Biopsy Devices
... by 2030, growing at a CAGR of 5.7% over the analysis period 2023-2030. Biopsy Guidance Systems, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$983.4 Million ... Read More
-
Fibromyalgia Therapeutics
... at a CAGR of 3.0% over the analysis period 2023-2030. Antiepileptics Drug Class, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.1 Billion by the end ... Read More
-
Apoptosis
... of 4.6% over the analysis period 2023-2030. Apoptosis Assay Kits, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$3.9 Billion by the end of the analysis ... Read More
-
Melanoma Therapeutics
... at a CAGR of 13.8% over the analysis period 2023-2030. Cutaneous Melanoma Therapeutics, one of the segments analyzed in the report, is expected to record a 13.8% CAGR and reach US$4.3 Billion by the end ... Read More
Research Assistance
